Interaction between widening of diameter of abdominal aorta and cardiovascular risk factors and atherosclerosis burden by Glauser, Frédéric et al.
IM - ORIGINAL
Interaction between widening of diameter of abdominal aorta
and cardiovascular risk factors and atherosclerosis burden
Fre´de´ric Glauser • Lucia Mazzolai •
Roger Darioli • Miche`le Depairon
Received: 7 December 2012 / Accepted: 26 March 2013 / Published online: 9 April 2013
 SIMI 2013
Abstract The aim of this study was to investigate influ-
ence of traditional cardiovascular risk factors (CVRF) and
subclinical atherosclerosis (ATS) burden on early stages of
abdominal aortic diameter (AAD) widening among adults.
2,052 consecutive patients (P) (39 % women), mean age
52 ± 13 years, were prospectively screened for CVRF,
ATS, and AAD. B-mode ultrasound was used to evaluate
the largest AAD and to detect carotid and femoral ath-
erosclerotic plaques. Mean AAD was 15.2 ± 2.8 mm.
Atherosclerotic plaques were detected in 71 % of patients.
Significant univariate correlation between AAD, traditional
CVRF, and ABS was found. However, multiple regression
analysis showed that only seven of them were significantly
and weakly correlated with AAD (R2 = 0.27, p \ 0.001).
On the other hand, a multivariate logistic analysis was used
to evaluate CVRF impact on enlarged AAD C25 mm
(EAAD) as compared to those with AAD \25 mm. These
factors did not account for more than 30 % of interaction
(R2 = 0.30, p = 0.001). Furthermore, despite a large pro-
portion of patients with high number of CVRF, and sub-
clinical ATS, rate of patients with AAD C25 mm was low
(1 %) and scattered regardless their CHD risk score or ATS
burden. In conclusion, these results suggest that although
some traditional CVRF and presence of ATS are associated
with early stages of EAAD, other determinants still need to
be identified for a better understanding of abdominal aortic
aneurysm pathogenesis.
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Introduction
Relative role of contributors to abdominal aortic aneu-
rysm (AAA) development is still a matter of debate.
Atherosclerosis (ATS) and AAA share common risk
factors, such as male sex, advanced age, and smoking
habits [1]. In contrast, robust data indicate that diabetes,
a major cardiovascular risk factor (CVRF), is inversely
correlated with presence and progression of AAA [1, 2].
Contribution of hypertension [2, 3], obesity [4, 5], and
hypercholesterolemia [6, 7] in AAA development remains
at present unclear. ATS and AAA differ also with respect
to histological findings. Media weakening involving
chronic inflammation, and extensive protease-mediated
degradation, is a main feature of AAA [8, 9]. Population-
based studies have shown that the presence of peripheral
vascular disease, or coronary heart disease (CHD), two
well-known atherosclerosis-linked diseases, are strong
predisposing factors for AAA development [10, 11].
Numerous epidemiological studies have evaluated the
correlation between CVRF and AAA. In contrast, only
few studies focused on the association between subclin-
ical ATS and CVRF with abdominal aortic diameter
(AAD) and enlarged AAD C25 mm (EAAD) which has
been demonstrated to be related to AAA risk [12]. To
better elucidate AAA pathogenesis, the purpose of this
study was to evaluate the influence of traditional CVRF
and subclinical ATS on early stages of AAD enlargement
among a population of adult patients at high risk of
cardiovascular diseases (CVD).
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Methods
Study population and cardiovascular risk factors
Consecutive 2,052 patients, aged 20–80 years, referred to
the Lipid Unit of a University Hospital for cardiovascular
risk assessment (Framingham coronary heart disease Risk-
Score), and/or therapeutic advice, were enrolled. All par-
ticipants gave informed written consent, and study protocol
was approved by the local ethics committee. CVRF were
prospectively collected as indicated here: patients
answered a detailed questionnaire collecting information
on family history of premature CHD, personal history of
CVD, diabetes, hypertension, blood lipids, and current
medications. Blood pressure was measured with a digital
blood pressure monitor. Body mass index (BMI) and the
Framingham coronary heart disease risk score were cal-
culated for all patients.
All patients underwent venous blood drawing following
an overnight fast. Total cholesterol, HDL cholesterol
(HDL-C), triglycerides, and glucose were determined on
fresh plasma samples using an auto-analyser (Cobras-Mira
PlusTM, Roche, Basel, Switzerland).
Hypertension was defined as SBP [140 mmHg and/or
DBP [90 mmHg, and/or current use of anti-hypertensive
agents. Smoking status was defined as current, former, or
never. Obesity was defined as BMI C30 kg/m2. Hyper-
cholesterolemia was defined as plasma total choles-
terol [6.5 mmol/L and/or current use of lipid lowering
therapy. Hypertriglyceridemia was defined as plasma tri-
glyceride level C1.7 mmol/L. Low HDL-C was defined
as an HDL-C \1 mmol/L. Diabetes was defined by the
current use of physician-prescribed antiglycemic medica-
tions or a fasting serum glucose level C7 mmol/L. CHD
was defined as a history of angina, acute coronary syn-
drome, or myocardial infarction. Cerebrovascular disease
was defined as any history of transient ischemic attack or
stroke. A positive family history of premature (men
aged \55, and women \65 years) CHD was considered
when there was a history of CHD in a first degree
relative.
Abdominal aorta evaluation
B-mode ultrasound (US) imaging, using a 3.5-MHz real-
time sector scanner, was used to measure AAD below renal
arteries. Abdominal aorta (AA) was examined both in
antero-posterior and lateral views. Maximum external
diameter within the infrarenal segment was measured.
AA was considered enlarged if diameter was C25 mm
but \30 mm, presence of AAA was defined as an AAD
C30 mm [13].
Subclinical atherosclerosis evaluation
Carotid and femoral arteries were analyzed by B-mode US
imaging. The analysis was performed with a colour duplex
scanner, using a high resolution 7 MHz linear array scan
head. The duplex scan was coupled with the M’ATHS
software performing semi-automatic on frame measures
(Metris, Paris, France). Carotid arteries were examined
from the lowest visible part, in the supraclavicular fossa, to
the submandibular angle. Femoral arteries were scanned
from 4 cm above, and 4 cm below, the inguinal bifur-
cation. Plaque was defined as a focal encroaching
of C1.2 mm into the arterial lumen measured from media-
adventitia to intima-lumen interface. Plaque thickness was
measured in its largest portion. Whenever more than one
plaque were present within the same arterial segment, only
the thickest one, measured in the longitudinal view, was
recorded. To quantify ATS burden an ‘‘Atherosclerosis
Burden Score’’ (ABS) ranging from 0 to 4, reflecting the
number of arterial bifurcations with plaques, was used.
Statistical analyses
All statistical analyses were performed using STATA 11.0
software (Stata corp., College station, TX, USA). The
results were expressed as mean ± standard deviation (SD),
categorical data as percentages, or interquartile ranges.
Comparison between categories was based on the t test for
continuous variables, and v2 test for categorical variables.
Association between aortic diameter, CVRF, and ABS
were assessed with univariate (Pearson’s and Spearman’s
rank) correlation, and multivariable linear modeling
regression analysis. Finally, interaction between EAAD,
CVRF, and other potential determinants, was assessed with
logistic multivariate regression analysis.
Results
Consecutive 2,052 patients were included in the study. At
the time of abdominal ultrasound, mean participants age
was 52 ± 13 years (range from 20 to 80 years old). Sixty
percent (1,245) of included patients were men. General
characteristics of studied population are summarized in
Table 1. There were significant statistical differences
between men and women concerning CVRF distribution.
Hypertension, current and past smokers, hypertriglyceri-
demia, low HDL-C, personal history of CVD (p \ 0.001),
and diabetes (p \ 0.01) were more frequent in men than in
women. In contrast, there were more women with hyper-
cholesterolemia and familial history of CHD than men
(p \ 0.001). The presence of subclinical ATS (ABS C 1)
was high in our study population (71 %).
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Mean AAD increased with age ranging from 12.3 ±
2.3 mm, in 20–29 years old men, to 15.3 ± 2.9 mm among
those 70–80 years old. Among women, AAD increased
from 14.0 ± 1.7 mm, in the 20–29 years old, to 18.4 ±
4.5 mm among those aged 70–80 years. Thus, men showed
significantly larger AAD than women (mean AAD of
16.4 ± 2.9 mm vs. 14.2 ± 1.9 mm, respectively; p \0.001)
(Fig. 1).
Prevalence of patients with either an EAAD C20 mm,
C25 mm, or AAA was respectively 4.0, 0.97, and 0.44 %.
Among subjects [65 years old, this prevalence was
respectively 3.9, 1.1, and 0.0 % among women and 17.2,
5.2, and 2.3 % among men.
As illustrated in Fig. 2, all parameters significantly
correlated with AAD. However, this figure indicates that
patients with EAAD are unequally far from regression line.
When performing analysis using the univariate linear
regression (Spearman’s correlation) a significant correla-
tion was observed between AAD and 12 of the 14 studied
parameters. Vice versa, when multivariate analysis was
performed, a correlation was found only for 6 of the
parameters (R2 = 0.27, p \ 0.001) (Table 2). However,
this correlation was no more significant for AAD C20 mm
(R2 = 0.14, p \ 0.54).
Probability to observe an EAAD C25 mm in association
with all these same parameters was also analyzed (Fig. 3).
Only gender, hypertriglyceridemia, current smoking, ABS,
and age were found to be significantly associated with
EAAD. However, these factors accounted for no more than
30 % of interaction (R2 = 0.30, p \ 0.001).
Discussion
The results presented herein indicate that ATS burden, and
some CVRF are positively correlated with AAD increase.
However, in our population of middle-aged patients with
increased cardiovascular risk, a subgroup of patients with
an EAAD C20 or 25 mm are unequally far from the
regression line regardless of CVRF and CHD risk score.
Fig. 1 Distribution of
abdominal aortic diameter by
gender
Table 1 Clinical characteristics
of patients
Statistical differences: women
versus men  p \ 0.01,
 p \ 0.001
Parameters Women Men All
Number (%) 807 (39) 1,245 (61) 2,052
Age (mean ± SD) 53.2 ± 14 51.5 ± 12 52.2 ± 12.9
Familial history of premature CVD (%) 23.8 18.4 20.5
Personal history of CVD (%) 4.3 10.9 8.3
Current smokers (%) 21.3 28.1 25.4
Past smokers (%) 15.9 29.6 24.2
Hypertension (%) 39 47.1 43.9
Hypercholesterolemia (%) 57.9 51.7 54.1
Hypertriglyceridemia (%) 22.5 40.2 33.2
Low HDL cholesterolemia (%) 9.4 26.3 19.6
Obesity (%) 13.4 15.3 14.4
Diabetes mellitus (%) 7.2 11.2 9.7
Number of patients with ABS C1 %) 64.6 74.5 70.6
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Few studies have been published assessing AAD
epidemiology and particularly concerning the role of tra-
ditional CVRF on aortic diameter variability and early
stages of AAA [14–18].
The present study is in agreement with the previous ones
showing a link between AAD enlargement with aging and
male gender [19, 20]. With age, arteries undergo changes
in their structural and functional capacities. Arterial wall
collagen-to-elastin ratio increases, as a result of decreased
elastic elements, leading to arterial dilation. In parallel,
arterial wall stiffness tends to increase [19]. Gender dif-
ferences in AAD are probably explained by higher height
and stiffness in AA of men [21, 22].
When concerning the other CVRF, a positive correlation
between BMI and AAD increment was observed in our
patients similarly to what reported by others [14–16]. This
Fig. 2 Correlation (Pearson’s) between the aortic abdominal diameter and cardiovascular risk factors and subclinical atherosclerosis
Table 2 Correlation between abdominal aortic diameter and traditional cardiovascular risk factors by univariate and multivariate regression
analysis
Variables Univariate regression analysis Multivariate analysis Coefficient b p
Coefficient q p
Gender (M vs. F) 0.474 0.000 0.371 0.000
Age (decades) 0.273 0.000 0.299 0.000
Familial history of premature CVD (yes vs. no) 0.058 0.009 -0.252 0.175
Personal history of CVD (yes vs. no) -0.086 0.000 0.009 0.738
Atherosclerosis burden score (0–4 units) 0.257 0.000 0.049 0.039
Current smoking (yes vs. no) -0.001 0.984 0.042 0.054
Past smoking (yes vs. no) 0.147 0.000 0.038 0.083
Diabetes mellitus (yes vs. no) 0.034 0.127 -0.028 0.183
Systolic blood pressure (mmHg) 0.148 0.000 -0.750 0.004
Diastolic blood pressure (mmHg) 0.0145 0.000 0.081 0.009
Total cholesterol (mmol/L) -0.134 0.000 -0.006 0.801
HDL-cholesterol (mmol/L) -0.168 0.000 -0.012 0.561
Triglycerides (mmol/L) 0.118 0.000 0.003 0.877
BMI (kg/m2) 0.259 0.000 0.078 0.000
q Spearman’s rank correlation coefficient, b standardized regression coefficient
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association may be explained by the ability of adipose
tissue to release adipokines. Indeed, it has been shown that
adipokines, including resistin, adiponectin, and leptin, can
play a paramount role in AAA pathogenesis [4].
Hypertension has limited effect on arterial diameter. In
contrast to Paivansalo et al. [16], we and others observed a
correlation between hypertension and weak AAD incre-
ment [14, 18, 19]. Increase in arteries diameter has been
advocated as a possible increase of fluid volume secondary
to sodium retention [23].
Although smoking constitutes a significant risk for
aneurysm development, two previous studies [14, 15],
evaluating impact of CVRF on AAD, have shown lack of
association between smoking and AAD. Paivansalo et al.
[16]. describe a significant correlation in smoking women
only (p \ 0.005). In our study, correlation was nearly
significant (p = 0.054). More recently, Johnsen et al. [17]
have shown that AAD increases markedly, between 18 and
29 mm, with current smoking (p \ 0.0001). Finally, in the
MESA study [18], the current smoking was independently
and significantly associated with increasing AAD
(p \ 0.01).
Lastly, we did not find any correlation between AAD
and diabetes. This result is in accordance with the previous
studies demonstrating inverse or no association between
AAD and diabetes [8, 14].
Statistical multivariate regression analysis revealed a
significant association between subclinical ATS burden
score (ABS) and AAD increment. This result is in agree-
ment with others demonstrating similar association using
different tools or techniques to quantify subclinical ATS
burden. Two studies [14, 18], demonstrated a significant
association between increasing AAD and presence and
extent of calcified ATS in AA and iliac arteries, or coro-
nary calcium using EBCT and calcium score. Patel et al.
[15] found similar association using ultrasounds to measure
AAD and IMT at several AA locations. AAD increase in
the presence of ATS may be explained by arterial remod-
elling: preservation of arterial lumen cross-sectional area in
spite of advancing ATS within the arterial wall (Glagov’s
phenomenon) [24]. Labropoulus et al. studied vessel
diameters throughout the vascular system in 67 ± 12-year-
old subjects with and without ATS and found that all
arteries dilate during early ATS plaque formation con-
firming the Glagov’s phenomenon throughout the vascular
tree [25]. Finally, Mohiaddin et al. [26] confirmed the
presence of Glagov remodeling in AA by cardiovascular
magnetic resonance, with an increment of 1 mm over
2 years in patients with arterial plaques.
An association between some CVRF and AAD does not
necessarily imply a link of causality. Multivariate regres-
sion analysis showed that CVRF and ABS accounted for
only 27 % (R2 = 0.27) of AAD variability in our study.
When concerning the subgroup of 20 patients with
EAAD C25 mm, only age, gender, current smoking,
hypertriglyceridemia, and ABS appeared to be significant
positive predictors. These risk factors are similar to those
known for AAA [27, 28].
Interestingly, despite a large proportion of patients with
diffuse ATS lesions (71 %) and C3 CVRF (37 %), prev-
alence of EAAD and AAA was low in our study popula-
tion, 0.97 and 0.44 %, respectively. Among men older than
65 years of age, the 5.2 % EADD and the 2.3 % AAA
prevalence were lower than those found in other studies.
Indeed, screening studies show that AAA occurs in 4–9 %
of individuals over the age of 60 [1, 3].
If ATS was the dominant feature of aortic enlargement,
the proportion of subjects with an aortic dilation should be
widely superior. In our study, the dilation of aortic diam-
eter was observed only in 2.4 % of patients with an ABS
Fig. 3 Interaction between
enlarged abdominal aortic
diameter (C25 mm) and
cardiovascular risk factors and
subclinical atherosclerosis, by
multivariate regression analysis
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score C3, and in 2.9 % of those with a history of coronary
artery disease. In the subgroup of patients with
AAD C20 mm (n = 83), these rates were 9.3 and 12.9 %,
respectively. Moreover, the subpopulation of patients with
AAD C25 mm was scattered regardless of CVRF number,
CHD risk score, or ATS burden. Herein, these traditional
CVRF accounted for a role in AAD enlargement for no
more than 30 % as expressed by the pseudo-R2. Similarly,
in the Tromsø Study, no consistent dose–response rela-
tionship between ATS and AAD was found [18]. These
observations strongly suggest that other factors than CVRF
and ATS are implicated in EAAD and ultimately AAA
formation. Thus, ATS may not be a causal but rather a
predisposing contributor for AAA. Indeed, recent studies
demonstrated the paramount role played by inflammation,
proteolysis, apoptosis, and oxidative stress in AAA
development and progression underlying the systemic
nature of the aneurysmal process [8, 29, 30].
The cross-sectional nature of the present study and the
lack of direct atheroma measurement within the aorta have
to be considered as limitations that possibly interfere on the
causal relationship between ATS, CVRF, and AAD
increment. Nevertheless, this study provides additional
evidence suggesting that pathophysiology of EAAD and
AAA is complex and multifactorial.
Our results demonstrate that traditional CVRF and ATS
only modestly contribute to AAD increase and are poor
predictors of EAAD, supporting the view that other key
factors need to be searched to further improve knowledge
of pathophysiology and AAA prediction.
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